Market revenue in 2023 | USD 3,618.3 million |
Market revenue in 2030 | USD 8,841.7 million |
Growth rate | 13.6% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 65.83% in 2023. Horizon Databook has segmented the Europe circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing government initiatives, rising disease burden of chronic illnesses, and presence of major manufacturers in this region drive market growth in the European region. In addition, countries are focusing on development of their manufacturing hubs and reducing dependency on Asian countries, such as India and China, for generic products & APIs.
Moreover, key players engaged in the development and commercialization of generic drugs are expected to contribute to market growth. However, stringent government regulation and uneven reimbursement policies in some EU countries may restrain market growth in Europe.
The geriatric population is at a high risk of chronic and infectious diseases, and the European region comprises a large geriatric population. According to Eurostat statistics, in 2019, over 90.4 million of the population in Europe was aged over 65. Moreover, Europe held a high market share, which can be attributed to presence of developed economies, such as Germany, the UK, France, and Italy.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe circulating tumor cells market , including forecasts for subscribers. This continent databook contains high-level insights into Europe circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account